Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Kabiven

&times

Overview

What is Kabiven?

KABIVENis a sterile, hypertonic emulsion, for central venous administration, in a Three Chamber Bag. The product contains no added sulfites.

Chamber 1 contains Dextrose solution for fluid replenishment and caloric supply.

Chamber 2 contains the Amino Acid solution with Electrolytes, which comprises essential and nonessential amino acids provided with electrolytes.

Chamber 3 contains Intralipid 20% (a 20% Lipid Injectable Emulsion), prepared for intravenous administration as a source of calories and essential fatty acids.

See below for formulations of each chamber and Table 2 for strength, pH, osmolarity, ionic concentration and caloric content of KABIVEN when all the chambers are mixed together.

Chamber 1:

Chamber 2:

Chamber 3:

The soybean oil is a refined natural product consisting of a mixture of neutral triglycerides of predominantly unsaturated fatty acids with the following structure:

where  are saturated and unsaturated fatty acid residues.  The major component fatty acids are linoleic (48 to 58 %), oleic (17 to 30%), palmitic (9 to 13%), linolenic (5 to 11%) and stearic acid (2.5 to 5%).   These fatty acids have the following chemical and structural formulas:

Purified egg phosphatides are a mixture of naturally occurring phospholipids which are isolated from the egg yolk. These phospholipids have the following general structure:

  contain saturated and unsaturated fatty acids that abound in neutral fats. R3 is primarily either the choline or ethanolamine ester of phosphoric acid.

Glycerin is chemically designated CHO and is a clear colorless, hygroscopic syrupy liquid. It has the following structural formula:

The container-solution unit is a closed system and is not dependent upon entry of external air during administration.  The container is overwrapped to provide protection from the physical environment and to provide an additional oxygen and moisture barrier when necessary.  An oxygen absorber is placed between the inner bag and the overpouch.

The container is not made with natural rubber latex or polyvinyl chloride (PVC).KABIVENcontains no more than 25 mcg/L of aluminum.



What does Kabiven look like?



What are the available doses of Kabiven?

KABIVEN is a sterile, hypertonic emulsion in a three chamber container.  The individual chambers contain one of the following respectively: amino acids and electrolytes, dextrose, or lipid injectable emulsion. Table 2 describes the individual components of KABIVEN.

Table 2: Contents of KABIVEN when mixed

What should I talk to my health care provider before I take Kabiven?

Renal Impairment:

®

2.4

8.7

How should I use Kabiven?

KABIVEN is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.  KABIVEN may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients.

Limitations of Use:

KABIVEN is not recommended for use in pediatric patients under the age of 2 years, including preterm infants because the fixed content of the formulation does not meet the nutritional requirements of this age group   .

For intravenous infusion only into a central vein. (, )

Recommended dosage depends on clinical status, body weight and nutritional requirements. ()

Adult dosage: 19 to 38 mL/kg/day (0.63 to 1.26 g/kg/day of protein, 1.85 to 3.71 g/kg/day of dextrose, 0.74 to 1.48 g/kg/day of lipid) ()

The maximum infusion rate is 2.6 mL/kg/hour (corresponding to 0.09 g/kg/hour of amino acids, 0.25 g/kg/hour of dextrose, the limiting factor, and 0.1 g/kg/hour of lipid). The recommended infusion period is 12 to 24 hours. ()


What interacts with Kabiven?

Sorry No Records found


What are the warnings of Kabiven?

Sorry No Records found


What are the precautions of Kabiven?

Sorry No Records found


What are the side effects of Kabiven?

Sorry No records found


What should I look out for while using Kabiven?

The use of KABIVEN is contraindicated in patients with the following:

[See and ]


What might happen if I take too much Kabiven?

In the event of overdose, fat overload syndrome may result .  Stop the infusion of KABIVENto allow lipids to clear from serum. The effects are usually reversible after the lipid infusion is stopped. If medically appropriate, further intervention may be indicated.  The lipid administered and fatty acids produced are not dialyzable.


How should I store and handle Kabiven?

Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.Keep out of the reach of children.Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.Keep out of the reach of children.Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.Keep out of the reach of children.Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.Keep out of the reach of children.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.KABIVEN is a sterile emulsion available in the following 4 sizes:NDCVolume63323-712-25              2,566 mL63323-712-20              2,053 mL63323-712-15              1,540 mL63323-712-10              1,026 mLExposure of pharmaceutical products to heat should be minimized.  Avoid excessive heat.  Protect from freezing.  If accidentally frozen, discard the bag.  It is recommended that the product be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. Do not remove container from overpouch until intended for use. After breaking the vertical seals, chemical and physical in-use stability of the mixed three chamber bag has been demonstrated for 48 hours at 25°C (77°F).  If not used immediately, the activated bag can be stored for up to 7 days under refrigeration [2° to 8°C (36º to 46°F)]. After removal from refrigeration, the activated bag should be used within 48 hours.  The product should be used immediately after the introduction of additives.  If not used immediately, the storage time and conditions prior to use should not be longer than 24 hours at 2° to 8°C (36° to 46°F).  After removal from storage at 2° to 8°C (36° to 46°F), the admixture should be infused within 24 hours.  Any mixture remaining must be discarded.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

KABIVEN is used as a supplement or as the sole source of nutrition in patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. 

The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source of energy.

The administered dextrose is oxidized to carbon dioxide and water, yielding energy.

Intravenously administered lipids provide a biologically utilizable source of calories and essential fatty acids.  Fatty acids serve as an important substrate for energy production.   The most common mechanism of action for energy derived from fatty acid metabolism is beta- oxidation.  Fatty acids are important for membrane structure and function, precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression.

Non-Clinical Toxicology
The use of KABIVEN is contraindicated in patients with the following:

[See and ]

Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.

Calcium channel blockers may also have an additive effect when given with atenolol (see ).

Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers.

Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers.

Beta-blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta-blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta-blockers should be delayed for several days after clonidine administration has stopped.

Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers.

Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta-blockers in the acute myocardial infarction setting.

While taking beta-blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.

Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Deaths in preterm infants after infusion of intravenous lipid emulsions have been reported. Autopsy findings included intravascular lipid accumulation in the lungs.

Preterm and small for gestational age infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.

The safe and effective use of KABIVEN injection in pediatric patients, including preterm infants, has not been established.   KABIVEN is not recommended for use in pediatric patients under the age of 2 years including preterm infants.

The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).